Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma

This study is testing a combination of three drugs — SHR-8068, adebrelimab (an immunotherapy), and bevacizumab (a drug that blocks blood vessel growth) — in people with advanced liver cancer (hepatocellular carcinoma or HCC) that cannot be surgically removed. **You may be eligible if...** - You are between 18 and 75 years old - You have advanced liver cancer confirmed by pathology - You have not received prior immunotherapy for liver cancer - You have had no more than 1 prior line of treatment - Your overall health and liver function are adequate - You have at least one measurable tumor **You may NOT be eligible if...** - You have a rare subtype of liver cancer (fibrolamellar, sarcomatoid, or mixed cholangiocarcinoma) - Your liver function is severely impaired - You have active autoimmune disease or severe infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.